COSMO Pharmaceuticals SA (0RGI) — Financial Flexibility Index
COSMO Pharmaceuticals SA (0RGI) has a Financial Flexibility Index of -0.04x as of June 2026. Free cash flow of £-5.20 Million (operating CF £-7.38 Million minus capex £2.18 Million) represents 0% of total liabilities (£121.91 Million). Check 0RGI total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
COSMO Pharmaceuticals SA Financial Flexibility Index (2004–2025)
Historical Financial Flexibility Index trend for COSMO Pharmaceuticals SA across 22 annual periods. For the full cash flow conversion analysis, see COSMO Pharmaceuticals SA cash flow conversion.
Annual Financial Flexibility Index for COSMO Pharmaceuticals SA (2004–2025)
Year-by-year free cash flow to debt coverage for COSMO Pharmaceuticals SA. Explore COSMO Pharmaceuticals SA (0RGI) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (GBP) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.06x | £-7.38 Million | £-11.62 Million | £123.36 Million | ▼ -105.1% |
| 2024 | 1.18x | £166.96 Million | £162.41 Million | £141.68 Million | ▲ +298.3% |
| 2023 | 0.30x | £36.97 Million | £33.62 Million | £124.94 Million | ▲ +134.2% |
| 2022 | 0.13x | £37.37 Million | £32.89 Million | £295.80 Million | ▲ +104.4% |
| 2021 | 0.06x | £18.10 Million | £12.61 Million | £292.88 Million | ▼ -29.2% |
| 2020 | 0.09x | £17.11 Million | £12.98 Million | £196.04 Million | ▲ +200.6% |
| 2019 | -0.09x | £-16.60 Million | £-18.85 Million | £191.43 Million | ▼ -89.7% |
| 2018 | -0.05x | £-8.27 Million | £-10.16 Million | £180.83 Million | ▼ -144.5% |
| 2017 | 0.10x | £2.86 Million | £-9.43 Million | £27.86 Million | ▼ -87.8% |
| 2016 | 0.84x | £23.53 Million | £21.69 Million | £27.92 Million | ▲ +177.4% |
| 2015 | -1.09x | £-37.35 Million | £-39.26 Million | £34.30 Million | ▼ -216.3% |
| 2014 | 0.94x | £68.65 Million | £66.45 Million | £73.33 Million | ▲ +112.4% |
| 2013 | 0.44x | £10.07 Million | £8.11 Million | £22.85 Million | ▼ -52.1% |
| 2012 | 0.92x | £30.26 Million | £27.76 Million | £32.89 Million | ▼ -8.3% |
| 2011 | 1.00x | £14.66 Million | £11.29 Million | £14.60 Million | ▲ +120.9% |
| 2010 | 0.45x | £15.21 Million | £7.79 Million | £33.46 Million | ▼ -49.9% |
| 2009 | 0.91x | £10.60 Million | £3.88 Million | £11.67 Million | ▲ +285.1% |
| 2008 | -0.49x | £-7.13 Million | £-12.52 Million | £14.53 Million | ▼ -306.2% |
| 2007 | -0.12x | £-1.46 Million | £-2.52 Million | £12.08 Million | ▼ -115.6% |
| 2006 | 0.78x | £14.18 Million | £6.08 Million | £18.27 Million | ▲ +262.9% |
| 2005 | 0.21x | £5.90 Million | £1.70 Million | £27.58 Million | ▲ +92.6% |
| 2004 | 0.11x | £2.70 Million | £261.00K | £24.34 Million | — |